TLDR Combining low-level laser therapy with topical corticosteroids effectively improved Lichen Planopilaris symptoms.
The study explores the effectiveness of combining low-level laser therapy (LLLT) with topical corticosteroid treatment for Lichen Planopilaris (LPP), a challenging scarring form of alopecia. Due to the patient's renal and hepatic comorbidities, systemic treatments were not viable, leading to a regimen of daily topical corticosteroid and weekly LLLT sessions over 2 months. The treatment resulted in significant improvement, with reduced inflammation and symptoms like itching and burning. The patient continued with an anti-inflammatory tonic and remained in remission 6 months post-treatment, highlighting the potential of this combined therapy approach for managing LPP.
4 citations
,
October 2023 in “Dermatology” The best treatment for lichen planopilaris is a combination of clobetasol, hydroxychloroquine, and N-acetylcysteine.
4 citations
,
May 2021 in “Lasers in Surgery and Medicine” Light therapy reduces scalp inflammation, boosts hair regrowth with Minoxidil 2%.
11 citations
,
February 2020 in “Dermatology and therapy” Low-Level Light Therapy significantly reduced inflammation and promoted hair regrowth in patients with Lichen planopilaris.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
1 citations
,
July 2018 in “Elsevier eBooks” Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.
April 2023 in “IP Indian journal of clinical and experimental dermatology” Lichen planus is a chronic autoimmune disease that is hard to treat and more common in women.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.